Patent search ap:"Jay TUNG" Page 1

1.

发明公开
Ultraviolet Face Shield Systems for Reducing Germ Transmission 审中-公开

公开(公告)号：US20230173117A1

公开(公告)日：2023-06-08

申请号：US17985350

申请日：2022-11-11

Applicant: Matthew Jay Tung

Inventor： Matthew Jay Tung

IPC: A61L2/10 , A61L2/26 , A41D13/11

CPC classification number: A61L2/10 , A61L2/26 , A41D13/1184 , A61L2202/11

Abstract: Several embodiments relating to ultraviolet face shield systems and methods of use are provided herein. Such face shield systems feature an ultraviolet light source capable of inactivating, destroying, or killing germs, bacteria, viruses, or other pathogens such as human coronavirus COVID-19, and protecting individual(s) from infection.

2.

发明申请
BETA-SECRETASE ENZYME COMPOSITIONS AND METHODS 审中-公开
Title translation: BETA-SECRETASE ENZYME组合物和方法

公开(公告)号：US20110281752A1

公开(公告)日：2011-11-17

申请号：US13070413

申请日：2011-03-23

Applicant: John P. Anderson , Guriqbal Basi , Minh Tam Doan , Normand Frigon , Varghese John , Michael Power , Sukanto Sinha , Gwen Tatsuno , Jay Tung , Shuwen Wang , Lisa McConlogue

Inventor： John P. Anderson , Guriqbal Basi , Minh Tam Doan , Normand Frigon , Varghese John , Michael Power , Sukanto Sinha , Gwen Tatsuno , Jay Tung , Shuwen Wang , Lisa McConlogue

IPC: C40B30/04 , C07K16/40 , C40B30/08 , C12N9/50 , G01N33/573

CPC classification number: C12N9/6478 , A01K2217/075 , A61K38/00 , H01Q1/364 , H01Q1/38 , H01Q3/44 , H01Q9/0407 , H01Q9/0442 , H01Q15/02

Abstract: Disclosed are various forms of an active, isolated β-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (β-APPwt and β-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate β-secretase. Inhibitors of β-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.

Abstract translation: 公开了各种形式的纯化和重组形式的活性，分离和分泌的酶。这种酶涉及积聚在患有阿尔茨海默病的个体的脑中的淀粉样蛋白斑块成分的产生。产生该酶单独或与其一些天然底物（＆bgr; -APPwt和＆bgr-APPsw）组合的重组细胞也被公开，以及针对这种蛋白质的抗体。这些组合物可用于选择调节和分泌酶的化合物的方法。抑制剂与分泌酶作为治疗神经变性疾病如阿尔茨海默氏病的治疗剂有牵连作用。

3.

发明授权
β-secretase enzyme compositions and methods 有权
Title translation: β-分泌酶组合物和方法

公开(公告)号：US07456007B1

公开(公告)日：2008-11-25

申请号：US09471669

申请日：1999-12-24

Applicant: John P. Anderson , Guriqbal Basi , Minh Tam Doan , Normand Frigon , Varghese John , Michael Power , Sukanto Sinha , Gwen Tatsuno , Jay Tung , Shuwen Wang , Lisa McConlogue

Inventor： John P. Anderson , Guriqbal Basi , Minh Tam Doan , Normand Frigon , Varghese John , Michael Power , Sukanto Sinha , Gwen Tatsuno , Jay Tung , Shuwen Wang , Lisa McConlogue

IPC: C12N9/64 , C12N15/00 , C12N5/00 , C12P21/06 , C12Q1/68

CPC classification number: C12N9/6421 , C07K14/8142 , C12Q1/6883 , C12Y304/23046

Abstract: Disclosed is an active, isolated β-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (APP and APPsw) are also disclosed. These compositions are useful for use in methods of selecting compounds that modulate β-secretase. Inhibitors of β-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.

Abstract translation: 公开了纯化和重组形式的活性，分离的β-分泌酶。这种酶涉及积聚在患有阿尔茨海默病的个体的脑中的淀粉样蛋白斑块成分的产生。也公开了单独或与其一些天然底物（APP和APPsw）组合产生该酶的重组细胞。这些组合物可用于选择调节β-分泌酶的化合物的方法。 β-分泌酶的抑制剂涉及作为治疗神经变性疾病如阿尔茨海默病的治疗剂。

4.

发明授权
Dipeptide inhibitors of β-secretase 失效
Title translation: β-分泌酶的二肽抑制剂

公开(公告)号：US07276484B2

公开(公告)日：2007-10-02

申请号：US11075232

申请日：2005-03-08

Applicant: Varghese John , Jay Tung , Roy Hom , Ashley Guinn , Lawrence Fang , Andrea Gailunas , Shumeye S. Mamo

Inventor： Varghese John , Jay Tung , Roy Hom , Ashley Guinn , Lawrence Fang , Andrea Gailunas , Shumeye S. Mamo

IPC: C07K5/06

CPC classification number: C07K5/101 , C07K5/0205

Abstract: Dipeptide derived inhibitors of the β-secretase enzyme are provided which are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of Aβ peptide in a mammal. The compounds of the invention provide useful methods of treatment by administration of these inhibitors to reduce Aβ peptide formation and in pharmaceutical compositions.

Abstract translation: 提供了二肽衍生的β-分泌酶的抑制剂，其可用于治疗阿尔茨海默病和以哺乳动物中Abeta肽沉积为特征的其它疾病。本发明的化合物提供了通过施用这些抑制剂以减少Aβ肽形成和药物组合物治疗的有用方法。

5.

发明授权
Tetrapeptide inhibitors of β-secretase 失效
Title translation: β-分泌酶的四肽抑制剂

公开(公告)号：US07169759B1

公开(公告)日：2007-01-30

申请号：US09594667

申请日：2000-06-15

Applicant: Varghese John , Jay Tung , Lawrence Fang , Shumeye S. Mamo

Inventor： Varghese John , Jay Tung , Lawrence Fang , Shumeye S. Mamo

IPC: A61K38/00

CPC classification number: A61K38/07

Abstract: Statine-derived peptide inhibitors of the β-secretase enzyme are provided which are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of Aβ peptide in a mammal. The compounds of the invention provide useful methods of treatment by administration of these inhibitors to reduce Aβ peptide formation and pharmaceutical compositions.

Abstract translation: 提供了β-分泌酶的来自Statine的肽抑制剂，其可用于治疗阿尔茨海默氏病和以哺乳动物中Abeta肽沉积为特征的其它疾病。本发明的化合物提供了通过施用这些抑制剂以减少Aβ肽形成和药物组合物的有效治疗方法。

6.

发明申请
4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases 失效
Title translation: 4-溴-5-（2-氯 - 苯甲酰基氨基）-1H-吡唑-3-羧酸酰胺衍生物和相关化合物作为缓激肽b1受体拮抗剂，用于治疗炎性疾病

公开(公告)号：US20060281733A1

公开(公告)日：2006-12-14

申请号：US10555519

申请日：2004-04-30

Applicant: Jay Tung , Albert Garofalo , Michael Pleiss , Jing Wu , David Wone , Ashley Guinn , Darren Dressen , R. Jeffrey Neitz , Jennifer Marugg , Martin Neitzel

Inventor： Jay Tung , Albert Garofalo , Michael Pleiss , Jing Wu , David Wone , Ashley Guinn , Darren Dressen , R. Jeffrey Neitz , Jennifer Marugg , Martin Neitzel

IPC: A61K31/5377 , A61K31/5513 , A61K31/55 , A61K31/496 , A61K31/4545 , A61K31/454 , A61K31/4152 , C07D403/02

CPC classification number: C07D401/14 , C07D231/16 , C07D231/40 , C07D401/12 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D453/02 , C07D471/04 , C07D471/08 , C07D487/08

Abstract: Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

Abstract translation: 公开了作为缓激肽B 1受体拮抗剂的式I和II化合物，并且可用于治疗由缓激肽B 1介导的哺乳动物中疾病或与疾病相关的不良症状， SUB>受体。某些化合物表现出增加的效力，并且还预期表现出增加的作用持续时间。

7.

发明申请
Novel compounds useful for bradykinin B1 receptor antagonism 审中-公开
Title translation: 用于缓激肽B1受体拮抗作用的新型化合物

公开(公告)号：US20060217362A1

公开(公告)日：2006-09-28

申请号：US11312757

申请日：2005-12-21

Applicant: Jay Tung , Darren Dressen , R. Neitz , Michael Pleiss

Inventor： Jay Tung , Darren Dressen , R. Neitz , Michael Pleiss

IPC: A61K31/5513 , A61K31/495 , A61K31/496 , A61K31/4545 , A61K31/445 , A61K31/397

CPC classification number: C07D249/18 , A61K31/00 , A61K31/397 , A61K31/445 , A61K31/4545 , A61K31/495 , A61K31/496 , A61K31/505 , A61K31/55 , A61K31/5513 , C07D243/14 , C07D243/24 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14

Abstract: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

Abstract translation: 公开了缓激肽B 1受体拮抗剂的化合物，并且可用于治疗由缓激肽B 1受体介导的哺乳动物中疾病或与疾病状况相关的不良症状。某些化合物表现出增加的效力，并且还预期表现出增加的作用持续时间。